Related Experiment Video
Updated: Jun 14, 2025

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Structural basis for CCR6 modulation by allosteric antagonists
David Jonathan Wasilko1, Brian S Gerstenberger2, Kathleen A Farley1
1Discovery Sciences, Medicine Design, Pfizer Inc., Groton, CT, USA.
Researchers determined inactive structures of CC chemokine receptor 6 (CCR6) bound to novel antagonists. This reveals how small molecules can block receptor activation, offering new avenues for treating inflammatory diseases.
Area of Science:
- Structural biology
- Pharmacology
- Immunology
Background:
- CC chemokine receptor 6 (CCR6) is a key target for chronic inflammatory diseases.
- Previous studies elucidated the active CCR6 structure bound to CCL20, detailing receptor activation mechanisms.
Purpose of the Study:
- To present inactive CCR6 structures in complex with novel allosteric antagonists.
- To elucidate the molecular basis of CCR6 antagonism by small molecules.
- To explore the allosteric communication within CCR6 upon antagonist binding.
Main Methods:
- X-ray crystallography was used to determine the ternary structures of CCR6 with antagonists SQA1/OXM1 and SQA1/OXM2.
- Biophysical techniques were employed to characterize antagonist binding and conformational states.
- Computational modeling was used to assess conformational preferences in solution.
Main Results:
- Two distinct inactive CCR6 structures were solved, complexed with oxomorpholine (OXM1, OXM2) and squaramide (SQA1) derivatives.
- Antagonists bind to separate extracellular and intracellular pockets, disrupting the receptor activation network.
- Minimal allosteric communication was observed between the two antagonist-binding sites, challenging conventional GPCR cooperativity models.
Conclusions:
- Small molecules can effectively antagonize CCR6 by stabilizing inactive conformations through distinct binding pockets.
- The findings provide structural insights into CCR6 allosteric antagonism, complementing knowledge of receptor activation.
- This work supports the development of novel therapeutics targeting CCR6 for inflammatory conditions.
More Related Videos
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
Related Concept Videos
Allosteric Regulation
Cooperative Allosteric Transitions
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...
Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...